Best Peptides for Men: What Has Evidence, Approved vs Research

Best Peptides for Men by Evidence: Approved vs Research

Evidence grade: A is an FDA-approved product with phase 3 or labelled trial data. C is phase 2 or small human studies short of an approval. D is animal data only, or no human trials we could find. Doses and results are those of the cited trials, not recommendations.

Percentages are as each label or paper reports them. The trials differ in length, population and estimand, so rows are not directly comparable. Sources are numbered at the bottom of the page.

Weight Loss: The Incretin Drugs and the Share of Men in the Trials

Fat loss is the one goal where peptide-class drugs have phase 3 data and approved labels. The Zepbound label reports that 68% of SURMOUNT-1 participants were female, and the Wegovy label reports 74% female for STEP 1, so men were a minority of both trials, roughly a third and a quarter. The retatrutide phase 2 trial, which is not an approved drug, enrolled 51.8% men. None of the abstracts we read reports a separate result by sex, so we do not claim one. The Zepbound label states that weight reduction was observed irrespective of age, sex, race, ethnicity, baseline BMI and glycemic status.

A 20 percent weight loss is not a 20 percent fat loss. Weight lost on these drugs includes lean tissue, and the trial abstracts above report body weight rather than body composition. For the dose steps, see the tirzepatide dosage guide, weight loss peptides and best peptides for fat loss. AOD-9604 is covered on its own page; we did not verify phase 3 data for it.

Tesamorelin: The One Growth Hormone Peptide With a Label

Tesamorelin is a growth hormone releasing factor analog. The Egrifta label limits it to the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, says long-term cardiovascular safety has not been established, and says it is not indicated for weight loss management because it has a weight-neutral effect. In the two 26-week label trials (2 mg daily, randomized 2:1), visceral adipose tissue fell by a mean 18% in study 1 and 14% in study 2, against changes of +2% and -2% on placebo, and IGF-1 rose by more than 100 ng/mL. The published trial randomized 412 patients, 86% of them men, and found visceral fat down 15.2% against up 5.0%. A smaller JAMA trial of 50 patients also reported a fall in liver fat, with a transient rise in fasting glucose at 2 weeks. All of this is in people with HIV and abdominal fat accumulation. Nothing in these papers tests it in otherwise healthy men. Our tesamorelin dosing page covers the unit arithmetic.

Muscle and Strength: GH Secretagogues

CJC-1295, ipamorelin and MK-677 raise growth hormone by acting on the pituitary, through the GHRH receptor or the ghrelin receptor. That much is shown in human studies. The CJC-1295 trials in healthy adults aged 21 to 61 found a single injection raised mean GH 2 to 10 fold for 6 days or more and IGF-I 1.5 to 3 fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days. Neither the abstract nor our searches turned up a trial showing muscle or strength gain. The only human ipamorelin trial we found tested it intravenously for postoperative ileus in 117 patients and found no difference from placebo, so it says nothing about muscle.

The longest body-composition data is for MK-677, which is a non-peptide ghrelin mimetic (see is it a peptide). In a 2-year trial of 65 healthy adults aged 60 to 81 on 25 mg daily, fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo at one year, but body weight rose 2.7 kg against 0.8 kg, fasting glucose rose and insulin sensitivity fell, and the increase in fat-free mass did not change strength or function. The ceiling is therefore a modest lean-mass change in older adults, not a steroid-like effect (see peptides vs steroids). Compound pages: CJC-1295 and ipamorelin, ipamorelin, muscle growth peptides and the muscle growth stack.

Recovery: BPC-157, TB-500 and the Wolverine Stack

A 2025 systematic review in orthopaedic sports medicine found 36 BPC-157 studies, 35 preclinical and one clinical, a retrospective study in which 7 of 12 patients with chronic knee pain reported relief lasting more than 6 months after intra-articular injection. It found no clinical safety data and put the half-life at under 30 minutes. FDA's compounding page (current as of 22 April 2026) says it has identified no, or only limited, safety information for BPC-157 for the proposed routes of administration. We did not verify human trials for TB-500. See the BPC-157 dosage page, the TB-500 guide, the Wolverine stack and recovery peptides. In-depth reading on cycle length is at peptide cycles.

Testosterone: What Peptides Do and Do Not Do

Growth hormone peptides do not act on testosterone. Tesamorelin and CJC-1295 are GHRH analogs, and ipamorelin and MK-677 act on the ghrelin receptor; the human studies above measured GH and IGF-1, not testosterone. A vendor page implying a testosterone effect is not describing anything in these papers.

Kisspeptin is the research exception. In a 2026 randomized, single-blind study of 15 healthy men, subcutaneous kisspeptin-10 infusions of 1.25 to 10.0 nmol/kg/h raised LH, FSH and testosterone against vehicle. After 5 days of continuous infusion testosterone stayed elevated but gonadotropins were back at vehicle levels, while daily 8-hour infusions for 12 days sustained the gonadotropin rise (mean LH increase +1.68 on day 1 and +1.14 on day 12). These were infusion protocols in a research setting, and kisspeptin is not an approved product.

Gonadorelin is GnRH, a different story. In a nonrandomized study of 28 men with congenital hypogonadotropic hypogonadism, a pulsatile gonadorelin pump produced spermatogenesis in 90% of 10 men, at a median of 6 months, against 83.3% of 18 men on cyclical gonadotropin therapy at a median of 14 months. That is specialist treatment of a rare condition, delivered by pump. When we searched DailyMed on 27 October 2026 all five gonadorelin labels returned were for veterinary products (cattle). Hormone drugs that men sometimes expect here are not peptides: hCG is a glycoprotein and enclomiphene is a small-molecule SERM.

The indirect route is weight loss. A 2025 meta-analysis of seven studies with 680 overweight or obese men found GLP-1 receptor agonists increased total testosterone, with larger rises in studies where weight fell more. The authors note the data do not show a direct action on the testis. This is not testosterone replacement therapy, which is a prescription treatment decided with a clinician.

Libido, Sleep and Hair

Vyleesi (bremelanotide, PT-141) is approved only for premenopausal women with HSDD, and its label says it is not indicated in men. We did not verify male trial data for this page, so we make no claim about its effect in men; see the PT-141 guide, which also covers the male question. Persistent erectile problems are a medical question before a peptide one. For sleep, see top peptides for sleep and the DSIP guide; we did not verify randomized sleep trials for DSIP for this update. For hair, GHK-Cu is the peptide most often named, but its human skin data is thin and we found no trial in male pattern hair loss: GHK-Cu guide, peptides for hair loss, longevity peptides.

An earlier version of this page carried a dosage chart and stack table with reported protocols. We removed them because the figures could not be tied to sources we opened. Reconstitution arithmetic for any vial is in the calculator above.

Where to buy

Disclosure. Links in this section may earn the Bureau a commission. The scorecard weighs documentation, shipping, service, price and longevity (independent test results sit beside the score, not in it), and the method is on the vendor scorecard page. Prices are list prices checked 2026-09-08 and change without notice.

• Amino Club, CJC-1295 and ipamorelin blend, 10mg, $59.99: the readers' pick for the muscle column, batch COA on every product page, code 100 for 20% off a first order. Amino Club review.
• Amino Club, tirzepatide (listed as GLP-2), 30mg, $59.99: $2.00 per mg; the price tracker shows the lowest today.
• Amino Club, BPC-157, 10mg, $39.99 and PSPeptides, TB-500: the repair pair. PSPeptides is the only scorecard vendor shipping outside the US, and code PEPTIDEBUREAU takes 10% off.
• Amino Club, PT-141, 10mg, $29.99: $3.00 per mg, lowest of the four vendors tracked for it. PT-141 guide.
• Amino Club, DSIP, 5mg, $29.99 and Amino Club, GHK-Cu, 50mg, $29.99: the sleep and scalp end, GHK-Cu at $0.60 per mg.
• Pantheon Peptides, tesamorelin: third-party lab verified, COA linked on the product page. Pantheon review.

Whatever you buy, check that the vendor publishes a batch-specific certificate of analysis rather than a generic one, and read how to buy peptides and how to spot a fake vendor before a first order. These are research compounds and nothing here is medical advice.

Frequently Asked Questions

What are the best peptides for men?

There is no best peptide for men, because peptides do not sort by sex. The ones with approved labels and phase 3 data are tirzepatide (Zepbound) and semaglutide (Wegovy) for weight loss, and tesamorelin (Egrifta) for excess abdominal fat in HIV-infected adults with lipodystrophy. Growth hormone secretagogues such as CJC-1295 and ipamorelin raise growth hormone or IGF-1 in small studies but are not approved, and BPC-157 has only one retrospective clinical study.

Do peptides raise testosterone?

Almost none do. CJC-1295, ipamorelin, tesamorelin and MK-677 act on the growth hormone axis rather than on testosterone. Kisspeptin-10 is the exception in research: in a 2026 study of 15 healthy men, subcutaneous kisspeptin-10 infusions raised LH, FSH and testosterone, and daily 8-hour infusions sustained the gonadotropin rise for 12 days. It is not an approved product. GLP-1 receptor agonists raised total testosterone in a meta-analysis of seven studies with 680 overweight or obese men, with the rise tracking weight loss.

Do peptides build muscle?

Not proven. In a 2-year randomized trial of 65 healthy adults aged 60 to 81, the oral ghrelin mimetic MK-677, which is not a peptide, increased fat-free mass by 1.1 kg against a 0.5 kg loss on placebo at one year, but the authors reported that the increase did not change strength or function. We found no randomized trial of CJC-1295 or ipamorelin showing muscle or strength gain.

Is tesamorelin a weight loss peptide?

No. The Egrifta label says it is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management because it has a weight-neutral effect. In the two label trials, visceral fat fell by about 18% and 14% over 26 weeks against changes of +2% and -2% on placebo.

Is PT-141 approved for men?

No. Vyleesi (bremelanotide) is approved for premenopausal women with hypoactive sexual desire disorder, and its label states it is not indicated for men. We did not verify male trial data for this page, so we make no claim about its effect in men.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.

Sources

1. Zepbound (tirzepatide) prescribing information, Eli Lilly, DailyMed, September 2026
2. Wegovy (semaglutide) prescribing information, Novo Nordisk, DailyMed, June 2026
3. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), Jastreboff et al, N Engl J Med, 2022
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), Wilding et al, N Engl J Med, 2021
5. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a phase 2 trial, Jastreboff et al, N Engl J Med, 2023
6. Egrifta WR (tesamorelin) prescribing information, Theratechnologies, DailyMed, August 2026
7. Metabolic effects of a growth hormone-releasing factor in patients with HIV, Falutz et al, N Engl J Med, 2007
8. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients, Stanley et al, JAMA, 2014
9. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults, Nass et al, Ann Intern Med, 2008
10. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults, Teichman et al, J Clin Endocrinol Metab, 2006
11. Ipamorelin for postoperative ileus after bowel resection, a phase 2 trial, Beck et al, Int J Colorectal Dis, 2014
12. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi et al, HSS J, 2025
13. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men, Yeung et al, Eur J Endocrinol, 2026
14. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men, Zhang et al, Am J Mens Health, 2019
15. Effects of GLP-1 receptor agonists on testicular dysfunction: a systematic review and meta-analysis, Salvio et al, Andrology, 2025
16. Vyleesi (bremelanotide) prescribing information, Cosette Pharmaceuticals, DailyMed, November 2025
17. DailyMed label search for gonadorelin, run 27 October 2026
18. Certain bulk drug substances for use in compounding that may present significant safety risks, FDA, content current as of 22 April 2026